Onkológia 5/2025
Combination of targeted therapy and immunotherapy: benefits, limits and open questions across diagnoses
The combination of targeted therapy and immunotherapy represents a new and dynamically evolving component of systemic oncologic treatment. Modern targeted therapy interferes with specific signaling pathways of tumor cells, while immunotherapy activates the host immune system through inhibition of immune checkpoint pathways. Regimens combining targeted therapy and immunotherapy have become a new standard of care in multiple cancer types. Despite substantial improvements in survival and an acceptable toxicity profile, controversies remain regarding patient selection, long-term adverse effects, and economic sustainability.
Keywords: targeted therapy, immunotherapy, combination therapy, toxicity, economic sustainability













